Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc
 
 
Facebook
 
ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Fatigue supplements are actually misbranded drugs: FDA

Thursday 10 May 2012

 

From the Chicago Tribune:

 

SupplementsFatigue supplements are actually misbranded drugs: FDA

May 4, 2012

A commercial website for people suffering from symptoms of chronic fatigue syndrome and fibromyalgia is rife with numerous illegal and misleading treatment claims, according to a recent warning letter sent to Dr. Jacob Teitelbaum by the U.S. Food and Drug Administration.

Teitelbaum, the medical director of the national Fibromyalgia and Fatigue Centers and author of several books on the topic, including “From Fatigued to Fantastic!” also unlawfully used his Facebook account to promote his products for disease treatment and prevention, the FDA said in the three-page letter.

More than a dozen of products on the Teitelbaum’s website endfatigue.com are marketed with therapeutic claims – meaning they can prevent, cure or treat disease -- which classifies them as drugs, the FDA said. But the supplements have not been approved as drugs by the FDA and do not have Generally Recognized As Safe or GRAS status.

The products are also promoted for treating conditions shouldn’t be self diagnosed or treated by non-medical practitioners, the FDA said. As a result, they don’t have adequate directions for use and are considered “misbranded.”

The FDA found the section on Teitelbaum’s website titled “Cures A-Z,” especially problematic because it listed a number of medical conditions with information on how to treat these conditions – along with products offered for sale through the website.

For example, it recommended “Eskimo 3 Fish Oil” as a treatment for Alzheimer’s Disease and claimed the product could “help treat any hidden depression which may be present.”

On the web page titled, “Breast Cancer,” under the heading, “TREATMENT,” it recommended Coenzyme Q10 and claimed that “[E]arly experience showed these nutrients may decrease breast cancer growth.” The Website also recommended specific supplements to treat colds and flu, hypertension, Parkinson’s Disease, heart disease and reduce cholesterol.

And in one example of a Facebook post, Teitelbaum wrote that he looked at a new study “showing that an herbal can beat the pants off a pain medication when managing arthritis,” according to the warning letter. In that post, he included a link titled, “Herbal Beats Pain Medication in New Arthritis Study,” which links to his website, endfatigue.com. “The webpage accessible through that link includes the claim described above for your Healthy Knees and Joints product,” the FDA said.

The FDA’s surveillance of false or misleading claims on Facebook is of great interest to the supplement industry. One important lesson for manufacturers is “the continued tendency for the FDA to consider social media as a source for illegal claims, when linked to products for sale,” wrote the Natural Products Insider. “There is no safe haven in Facebook or Twitter.”

In a statement, Teitelbaum characterized himself as a “patient advocate reporting on thousands of scientific studies.” His goal is to “help people become aware of the pros and cons of new research on both natural health products and prescription treatment options.”

Teitelbaum said he recognized the need for the regulations but was “surprised” by FDA’s letter. The “Cures A-Z” section is no longer on the site; Teitelbaum said he is working with the agency to address concerns.

“Current FDA regulations do not allow disease-related claims to be made for natural products, unless the product has gone through the FDA drug approval process, which can cost upward of $500 million, making this impossible for most non-patentable natural options,” he said.

“This often creates a difficult line between what is considered simply reporting on a research study result versus what is considered making a promotional product claim to treat a disease, even if the report is based on solid research.”

Teitelbaum vowed to keep advocating “for consumer access to truthful, reliable, information about the thousands of studies demonstrating the health benefits of natural dietary supplements and herbal products, while ensuring the language on the web site complies with FDA regulations.”

Still, after reading the warning letter, you could almost hear a collective sigh by agency staff. “The unlawful disease treatment and prevention claims made on your website were too numerous to list in this letter,” wrote Evelyn Bonnin, District Director of the FDA’s Baltimore District Office.

The FDA listed the following dietary supplements as being marketed as unapproved drugs but also noted the list was only a fraction of the violations.

  • Corvalen (D-Ribose)
  • Coenzyme Q10
  • Jigsaw Magnesium w/ SRT
  • BMR Complex (Thyroid Glandular)
  • Energy Revitalization System
  • Acetyl-L-Carnitine
  • Chol-less
  • Thymic Protein
  • Alpha Lipoic acid
  • Black Cohosh
  • Healthy Knees and Joints
  • Eskimo 3 Fish Oil

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus

Previous Previous Page